Neogenomics (NEO) Short-term Investments (2020 - 2025)

Neogenomics has reported Short-term Investments for 6 years, with the latest figure at $9.0 million in Q2 2025.

• For the quarter ending Q2 2025, Short-term Investments fell 72.65% year-over-year to $9.0 million; the trailing twelve-month figure through Jun 2025 stood at $9.0 million (down 72.65% YoY), and the FY2024 full-year result was $19.8 million, down 72.73% from the prior year.
• Short-term Investments for Q2 2025 stood at $9.0 million, down from $11.9 million in the prior quarter.
• The five-year high for Short-term Investments was $203.0 million in Q2 2021, with the low at $9.0 million in Q2 2025.
• Historically, Short-term Investments has averaged $116.0 million across 5 years, with a median of $131.3 million in 2023.
• Annual changes were most pronounced in 2021 — Short-term Investments soared 301.28% — and 2025, when it slumped 77.54%.
• Neogenomics' Short-term Investments stood at $198.6 million in 2021, then declined by 11.96% to $174.8 million in 2022, then plunged by 58.4% to $72.7 million in 2023, then slumped by 72.73% to $19.8 million in 2024, then tumbled by 54.81% to $9.0 million in 2025.
• The last three Short-term Investments figures came in at $9.0 million (Q2 2025), $11.9 million (Q1 2025), and $19.8 million (Q4 2024), per Business Quant data.